Abstract
Recently, cancer immunotherapy by immune checkpoint inhibitors has been considered
one of the pillars for the treatment of cancer. Nivolumab is the first immune checkpoint
inhibitor approved for lung cancer treatment in Japan. Although nivolumab has superior
survival benefits and fewer adverse events than cytotoxic agents, it can generate
dysimmune toxicities, known as immune-related adverse events. Although autoimmune
manifestations are well-known immune-related adverse events, the development of infectious
diseases is rare. Here, we report on a patient with advanced NSCLC in whom pulmonary
tuberculosis developed rapidly during nivolumab treatment and discuss the potential
mechanisms as well as what is known about infections during checkpoint inhibitor therapy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Thoracic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.N Engl J Med. 2015; 373: 123-135
- Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med. 2015; 373: 1627-1639
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review.Eur J Cancer. 2016; 54: 139-148
- PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.J Immunol. 2007; 178: 2714-2720
- Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection.J Immunol. 2006; 176: 3000-3009
- The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum.Proc Natl Acad Sci U S A. 2008; 105: 2658-2663
- Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis.J Leukoc Biol. 2010; 88: 233-240
- Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis.J Immunol. 2008; 181: 116-125
- Opportunistic infections in patients treated with immunotherapy for cancer.J Immunother Cancer. 2014; 2: 19
- Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.Lancet Infect Dis. 2005; 5: 361-373
Article info
Publication history
Published online: July 13, 2016
Accepted:
July 2,
2016
Received in revised form:
July 1,
2016
Received:
June 21,
2016
Footnotes
Disclosure: The authors declare no conflict of interest.
Identification
Copyright
© 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
